Medical and Elderly Care Endowment Schemes (Medifund Committees) Order 2015

Medical and Elderly Care Endowment
Schemes Act 2000

(Section 14)

Medical and Elderly Care Endowment Schemes (Medifund Committees) Order 2015

2025 REVISED EDITION

(2 June 2025)

[18 June 2015]

Citation

1.  This Order is the Medical and Elderly Care Endowment Schemes (Medifund Committees) Order 2015.

Medifund committees

2.—(1)  The Minister appoints the Medifund committees named in the first column of Parts 1, 2 and 3 of the Schedule for the purposes of Part 2 of the Act.

(2)  A Medifund committee named in the first column of Part 1 of the Schedule may —

(a) consider and approve applications under section 15 of the Act from all classes of eligible patients (other than the class of eligible patients mentioned in sub‑paragraph (4)(a)) in one or more approved institutions designated in the second column of Part 1 of the Schedule corresponding to the Medifund committee; and

(b) exercise the powers and perform the duties under Part 2 of the Act in relation to those approved institutions and classes of eligible patients.

(3)  A Medifund committee named in the first column of Part 2 of the Schedule may —

(a) in one or more approved institutions designated in the second column of Part 2 of the Schedule corresponding to the Medifund committee, consider and approve applications under section 15 of the Act from the classes of eligible patients specified opposite to the approved institutions in the third column of Part 2 of the Schedule; and

(b) exercise the powers and perform the duties under Part 2 of the Act in relation to those approved institutions and classes of eligible patients.

(4)  A Medifund committee named in the first column of Part 3 of the Schedule may —

(a) consider and approve applications under section 15 of the Act from an eligible patient who has received treatment or requires treatment involving the administration of any cell, tissue or gene therapy product from one or more approved institutions designated in the second column of Part 3 of the Schedule corresponding to the Medifund committee; and

(b) exercise the powers and perform the duties under Part 2 of the Act in relation to those approved institutions and the eligible patient.

(5)  For the purposes of sub-paragraph (4), the hospital charges, fees and other expenses forming the subject matter of an application include any hospital charges, fees and other expenses incurred by the eligible patient for any other treatment received by him or her from the approved institution which does not involve the administration of any cell, tissue or gene therapy product if, and only if, such other treatment is received within the same hospitalisation period as the treatment involving the administration of any cell, tissue or gene therapy product from the approved institution.

(6)  In this paragraph —

“cell, tissue or gene therapy product” has the meaning given by the First Schedule to the Health Products Act 2007;

“hospitalisation period” means the period starting on the day an eligible patient is admitted to an approved institution and ending on (and including) the day the eligible patient is discharged from the approved institution.